All really valuable information, though Albemarle are confusing the situation by referring more to conversion plants, mostly hydroxide.
CXO is a better example for WIN.
15 Aug 2016: CXO acquires Finniss
23 Sep 2016: first assays (Widgie here in December 2022)
8 May 2017: maiden resource (Widgie need this)
19 Oct 2017: CXO applied for mining lease (Widgie have this)
25 Jun 2018: pre feasibility study released (Widgie need a quicker DSO study, see RDT)
21 Jan 2019: mineral lease granted (Widgie have this)
9 Aug 2021: funding secured (Widgie need a fraction of this $ for DSO)
26 Oct 2021: construction begins
3 Oct 2022: DSO sold
30 Dec 2022: DSO shipped
Important differences:
CXO didn't have a DSO strategy until 6 mths into their spodumene plant construction, so it wasn't optimised.
CXO spent 1.5 years waiting for a mining lease which WIN already have.
CXO designed their study in more detail and at a much higher cost, because it was a full concentrator. See other RDT for timeframes on their DSO study.
CXO constructed an underground mine, while WIN is open pit.
Once you take everything into account, WIN may need:
Up to 8mths to get a maiden resource (from Dec 2022)
Up to 6mths to do a DSO study concurrently with drilling
Up to 12mths to construct depending on where they can cut corners compared to CXO.
It's tight, but doable. Spodumene never went above $1000 per tonne before July 2022. CXO also endured a bust cycle & covid, which reduced their urgency.
Someone can chime in if I've missed something.
- Forums
- ASX - By Stock
- Ann: Gillett Resource Expands in Size and Confidence - Updated
WIN
win metals ltd
Add to My Watchlist
0.00%
!
1.8¢

All really valuable information, though Albemarle are confusing...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.901M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.8¢ | $1.625K | 90.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 1329842 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 1299996 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 1329842 | 0.018 |
3 | 1270000 | 0.017 |
2 | 135000 | 0.015 |
1 | 40000 | 0.014 |
1 | 76920 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 1299996 | 4 |
0.020 | 71781 | 3 |
0.021 | 722178 | 5 |
0.022 | 31119 | 1 |
0.023 | 91904 | 2 |
Last trade - 09.59am 26/06/2025 (20 minute delay) ? |
Featured News
WIN (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online